AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21942363
Drug: Pure-phase multiporous
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure-phase multiporous beta-tricalcium phosphate (beta-TCP) packed into the bone gaps around the implants (Group B)
Trial: 18445665
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy (66 microg/kg.d) for 2 years in group 3 (78 patients from group 1)
Trial: 18445665
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group 1 and group 2 without GH therapy)
Trial: 20069533
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation Therapy (CST), a 14-session group treatment
Trial: 16101937
Drug: Live Lactobacillus
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live Lactobacillus paracasei (LP33) - 5 x 10(9) colony-forming units/capsule, 2 capsules per day for 30 days
Trial: 16101937
Drug: Heat-killed Lactobacillus
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-killed Lactobacillus paracasei (LP33) - 5 x 10(9) colony-forming units/capsule, 2 capsules per day for 30 days
Trial: 16101937
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 2 capsules per day for 30 days
Trial: 12468781
Drug: Oral citicoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral citicoline (500, 1000, and 2000 mg)
Trial: 12468781
Drug: Oral citicoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral citicoline (2000 mg)
Trial: 8067216
Drug: Interpleural analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpleural analgesia with bupivacaine 5 mg.ml‐1 and 5 microgram epinephrine, 30 ml bolus, continuous infusion at 7 ml/hour
Trial: 8067216
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with bupivacaine 3.75 mg.ml‐1 and 5 microgram epinephrine, 5 ml bolus, continuous infusion at 5 ml/hour
Trial: 3289648
Drug: Alprazolam 4
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam 4 mg/day
Trial: 3289648
Drug: Chlormethiazole 3.072
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormethiazole 3.072 g/day (equivalent to 8 g of the edisylate)
Trial: 30683060
Drug: Pharmacist's medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist's medication review combined with a communication pathway to GPs and nursing home staff, facilitation of change in interprofessional cooperation, educational training, and a toolbox for implementation.
Trial: 30683060
Drug: Pharmacist's medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist's medication review and interprofessional cooperation measures.
Trial: 29317015
Drug: BDP BAI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP BAI 320 μg/day
Trial: 29317015
Drug: BDP BAI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP BAI 640 μg/day
Trial: 29317015
Drug: BDP MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP MDI 320 μg/day
Trial: 25037985
Drug: Control of
RxNorm normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control of physiotherapist twice monthly (1 day/2 weeks) - Group 2
Trial: 20303323
Drug: 75 IU
RxNorm normalized name: Follitropin Beta 75 IU/0.5 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 IU recombinant follicle-stimulating hormone (rFSH)/day
Trial: 17354182
Drug: Adjuvant hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant hypertonic glucose solution injections
Trial: 15371046
Drug: Paraffin bath
RxNorm normalized name: Paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraffin bath treatment combined with hand exercise
Trial: 11591551
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (two 200-microg puffs bid; budesonide group, n = 19)
Trial: 11591551
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (symptomatic group, n = 19)
Trial: 9845852
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg day‐1 and step 1 diet
Trial: 9845852
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg day‐1 and step 2 diet
Trial: 3058228
Drug: High-dose nandrolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nandrolone decanoate for 3 months in Group II (44 patients with moderate or chronic severe aplastic anemia)
Trial: 21048773
Drug: Walnut supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut supplementation (15 g/day for 4 weeks)
Trial: 12867226
Drug: Fexofenadine 180
RxNorm normalized name: fexofenadine 180 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 180 mg alone
Trial: 12867226
Drug: Fexofenadine 180
RxNorm normalized name: fexofenadine 180 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 180 mg with alcohol (0.3 g/kg body weight)
Trial: 12867226
Drug: Hydroxyzine 50
RxNorm normalized name: hydroxyzine hydrochloride 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 50 mg with alcohol
Trial: 10559084
Drug: Omeprazole, 40
RxNorm normalized name: Omeprazole, 40 mg oral delayed release capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 40 mg qd for 8 weeks
Trial: 6605682
Drug: Fenbufen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenbufen (600 or 900 mg daily)
Trial: 30758216
Drug: Vehicle formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle formulation (chitosan and PEG 400)
Trial: 27585808
Drug: Guided self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-help intervention (based on problem-solving therapy)
Trial: 26470874
Drug: Single ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of 20(S)-ginsenoside Rg3 (10-60 mg)
Trial: 26470874
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 20(S)-ginsenoside Rg3 (30 mg for 15 days)
Trial: 17612905
Drug: Single-tablet combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-tablet combination therapy
Trial: 10634963
Drug: Glucagon infusion
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon infusion
Trial: 2248077
Drug: Moclobemide 300‐500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 300‐500 mg daily for 4 weeks
Trial: 2248077
Drug: Moclobemide 150‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 150‐300 mg daily for 6 weeks
Trial: 2248077
Drug: Mianserin 75‐125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 75‐125 mg daily for 4 weeks
Trial: 2248077
Drug: Maprotiline 75‐150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline 75‐150 mg daily for 6 weeks
Trial: 26490018
Drug: Probiotic drink
RxNorm normalized name: CVS Probiotic Drink Mix 10 Billion CFU Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic drink containing Lactobacillus casei Shirota, administered twice a day for 4 weeks.
Trial: 26490018
Drug: Placebo drink,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink, administered for 4 weeks.
Trial: 24626000
Drug: Theophyline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophyline (4 mg/kg IV loading dose, followed by 200 mg orally three times daily for four days)
Trial: 20550483
Drug: Orodispersible tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orodispersible tablets (ODTs) incorporating PEG solid dispersion of meloxicam (MLX)
Trial: 20550483
Drug: Marketed immediate
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed immediate release MLX tablet
Trial: 20386003
Drug: Enhanced depression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced depression treatment (problem-solving therapy and/or pharmacotherapy, then a stepped-care approach)
Trial: 12952293
Drug: IL-4 Pseudomonas
RxNorm normalized name: Il-4 pseudomonas toxin fusion protein (il-4(38-37)-pe38kdel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-4 Pseudomonas exotoxin (NBI-3001) administered intratumorally via convection-enhanced delivery at doses of 6 microg/ml x 40 ml, 9 microg/ml x 40 ml, 15 microg/ml x 40 ml, or 9 microg/ml x 100 ml.
Trial: 11028576
Drug: Intracutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous injection
Trial: 8630719
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg qd
Trial: 1428726
Drug: Difluorodeoxycytidine (dFdC)
RxNorm normalized name: 2',2'-Difluorodeoxycytidine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Difluorodeoxycytidine (dFdC) administered by 30 minute infusion at doses of 5-90 mg/m2
Trial: 1428726
Drug: Difluorodeoxycytidine (dFdC)
RxNorm normalized name: 2',2'-Difluorodeoxycytidine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Difluorodeoxycytidine (dFdC) administered by 5 minute bolus at doses of 30-150 mg/m2
Trial: 29152718
Drug: KLOX BioPhotonic
RxNorm normalized name: Kloxxado
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KLOX BioPhotonic System (LED blue light phototherapy with photo-converter chromophores), treated hemiface, 12 weeks total (6 weeks treatment + 6 weeks follow-up)
Trial: 29152718
Drug: Control hemiface
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control hemiface (untreated during Main trial), received 6 weeks of treatment (twice weekly)
Trial: 26692004
Drug: Henagliflozin 5
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Henagliflozin 5 mg/day
Trial: 26692004
Drug: Henagliflozin 10
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Henagliflozin 10 mg/day
Trial: 26692004
Drug: Henagliflozin 20
RxNorm normalized name: bexagliflozin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Henagliflozin 20 mg/day
Trial: 20211542
Drug: Arthrocentesis plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis plus intra‐articular injection of tenoxicam
Trial: 15914614
Drug: Oral angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral angiotensin II receptor blocker (ARB)
Trial: 10902989
Drug: Energy and
RxNorm normalized name: Energy And Endurance Testosterone UP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy and micronutrient supplement (1171 kJ + 12 mg iron)
Trial: 10902989
Drug: Energy and
RxNorm normalized name: Energy And Endurance Testosterone UP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy and micronutrient supplement (209 kJ + 12 mg iron)
Trial: 10902989
Drug: Energy and
RxNorm normalized name: Energy And Endurance Testosterone UP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy and micronutrient supplement (104 kJ)
Trial: 8770304
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of ketorolac administered via Jackson‐Pratt drain or intravenously
Trial: 8770304
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) administered via Jackson‐Pratt drain or intravenously
Trial: 30485400
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 mg at weeks 0 and 4 and every 8 weeks thereafter
Trial: 30485400
Drug: adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab 80 mg at week 0, 40 mg at week 1, and 40 mg every 2 weeks thereafter
Trial: 20462041
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of midazolam (0.04 mg/kg)
Trial: 20462041
Drug: Combined epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined epidural infusion and EA
Trial: 12419082
Drug: sequential estradiol‐norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential estradiol‐norethisterone acetate regimen
Trial: 10993623
Drug: Minimum 5-day
RxNorm normalized name: sipuleucel-T
DrugBank: Sipuleucel-T (DB06688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimum 5-day IV antibiotic course (Group 1)
Trial: 10993623
Drug: No minimum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No minimum IV antibiotic requirement (Group 2)
Trial: 1459376
Drug: Ethanol by
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol by ingestion (95%‐0.84 ml/kg)
Trial: 28119496
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 125 mg of bosentan twice daily plus 10 μg of iloprost 4‐6 times/d
Trial: 28119496
Drug: Bosentan monotherapy
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan monotherapy with 125 mg of bosentan twice daily
Trial: 28119496
Drug: Iloprost monotherapy
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost monotherapy with 10 μg of iloprost 4‐6 times/d
Trial: 23283501
Drug: Oral-lipid-tolerance tests
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-lipid-tolerance tests (OLTTs)
Trial: 12971730
Drug: Nocturnal BCAA
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nocturnal BCAA administration
Trial: 12971730
Drug: Daytime BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daytime BCAA administration
Trial: 10755543
Drug: MMF 1
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 1 g/day
Trial: 10755543
Drug: MMF 2
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 2 g/day
Trial: 9294478
Drug: Methylprednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (40 mg days -1, 0, 1, 7, 8, and 9 of each cycle)
Trial: 24349598
Drug: High-dose prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisolone (2 mg/kg)
Trial: 20107293
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies for PHN pain relief
Trial: 18390971
Drug: Cetuximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400 mg/m² day 1 followed by 250 mg/m² weekly) plus Irinotecan (350 mg/m² every 3 weeks)
Trial: 16797948
Drug: Sustained-release metformin
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release metformin hydrochloride pellets (F-2, F-3)
Trial: 16797948
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release metformin tablet (Glucophage)
Trial: 14505991
Drug: Phytosterol ester-enriched
RxNorm normalized name: phytosterol esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol ester-enriched vegetable oil (0.45 g/day as free sterol)
Trial: 14505991
Drug: Control vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vegetable oil (0.04 g phytosterol as the major free sterol)
Trial: 10811340
Drug: Interferon and
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon and ribavirin (3 million units of alpha‐interferon three times weekly with 1000 mg of ribavirin daily)
Trial: 10811340
Drug: Interferon and
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon and amantadine (3 million units of alpha‐interferon with 200 mg of amantadine daily)
Trial: 9023837
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with cisplatin-containing regimens followed by radiotherapy
Trial: 9023837
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy after radiotherapy
Trial: 7816256
Drug: Desferrioxamine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine 15 mg/kg administered 1 hour before dialysis
Trial: 7816256
Drug: Desferrioxamine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine 15 mg/kg administered 44 hours before dialysis
Trial: 2897784
Drug: Nizatidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (300 mg, once daily at bedtime)
Trial: 2897784
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg, once daily at bedtime)
Trial: 21337296
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy plus resource activation (RFCBT)
Trial: 19417872
Drug: Xylitol lozenges
RxNorm normalized name: xylitol Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol lozenges (5 pieces/day, 2 g each) for 4 weeks
Trial: 19417872
Drug: Sorbitol lozenges
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorbitol lozenges (5 pieces/day, 2 g each) for 4 weeks
Trial: 15188351
Drug: MRA (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRA (8 mg/kg body weight)
Trial: 15188351
Drug: MRA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRA (4 mg/kg body weight)
Trial: 8521306
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms.kg-1
Trial: 2334454
Drug: ibopamine solution
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibopamine solution 1%
Trial: 2334454
Drug: tropicamide solution
RxNorm normalized name: Tropicamide
DrugBank: Tropicamide (DB00809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tropicamide solution 1%
Trial: 2334454
Drug: ibopamine solution
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibopamine solution 0.25% and 0.50%
Trial: 103404
Drug: Meglumine iotroxate
RxNorm normalized name: Meglumine iotroxate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine iotroxate (3.6 g iodine)
Trial: 103404
Drug: Meglumine iodoxamate
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meglumine iodoxamate (5.3 g iodine)
Trial: 103404
Drug: Meglumine ioglycamate
RxNorm normalized name: meglumine ioglycamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine ioglycamate (5.3 g iodine)
Trial: 18646005
Drug: interesterified butter
RxNorm normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: interesterified butter blend with fish oil (352 mg n‐3 long‐chain PUFA)
Trial: 10949982
Drug: Teicoplanin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (10 mg x kg(‐1) x d(‐1))
Trial: 10949982
Drug: Vancomycin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (40 mg x kg(‐1) x d(‐1)) plus ceftazidime and netilmicin
Trial: 1684749
Drug: Methyldopa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (500 mg to 1 g daily)
Trial: 1684749
Drug: Rilmenidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine (1 to 2 mg daily)
Trial: 24646429
Drug: Brief Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Intervention (BI) for medication-overuse headache (MOH)
Trial: 17265549
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (manual needle stimulation of 19 acupoints, 30 min sessions, 10 sessions over a year)
Trial: 16105122
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole initially and maintenance therapy with a standard dose H(2)‐RA
Trial: 16105122
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of lansoprazole initially and maintenance therapy of 15 mg lansoprazole
Trial: 16105122
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of lansoprazole once daily for 16 weeks